UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel

Methods and Findings in Experimental and Clinical Pharmacology, 2006-06, Vol.28 (5), p.315

2006

Volltextzugriff (PDF)

Criticality of pH for accurate fluorometric measurements of dipyridamole levels in biological fluids

Methods and findings in experimental and clinical pharmacology, 2005-03, Vol.27 (2), p.95-100

2005

Volltextzugriff (PDF)

Escitalopram, but not its major metabolites, exhibits antiplatelet activity in humans

Journal of clinical psychopharmacology, 2006-04, Vol.26 (2), p.172-177

2006

Volltextzugriff (PDF)

Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke : For the plavix use for treatment of stroke (PLUTO-stroke) trial

Stroke (1970), 2005-10, Vol.36 (10), p.2289-2292

2005

Volltextzugriff (PDF)

Dipyridamole Decreases Protease-Activated Receptor and Annexin-V Binding on Platelets of Poststroke Patients with Aspirin Nonresponsiveness

Cerebrovascular diseases (Basel, Switzerland), 2006-01, Vol.21 (1-2), p.98-105

2006

Volltextzugriff (PDF)

Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: A randomized, single-blind, 30-day trial

Clinical therapeutics, 2008-02, Vol.30 (2), p.249-259

2008

Volltextzugriff (PDF)

Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial

The American heart journal, 2006, Vol.151 (1), p.92-99

2006

Volltextzugriff (PDF)

Criticaly of pH for accurate fluorometric measurements of dipyridamole levels in biological fluids

Methods and Findings in Experimental and Clinical Pharmacology, 2005, Vol.27 (2), p.95

2005

Volltextzugriff (PDF)

Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease

Thrombosis and haemostasis, 2008-07, Vol.100 (1), p.76-82

2008

Volltextzugriff (PDF)

Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge

Thrombosis and haemostasis, 2014-01, Vol.111 (1), p.3-7

2014

Volltextzugriff (PDF)

Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?

Expert review of cardiovascular therapy, 2015-12, Vol.13 (12), p.1333-1344

2015

Volltextzugriff (PDF)

Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer : The VERify Thrombosis risk ASsessment (VERITAS) study

Thrombosis research, 2007, Vol.119 (3), p.277-284

2007

Volltextzugriff (PDF)

The Constant Magnetic Field Influence on Diffusion of63Ni in α-Fe

Physica status solidi. A, Applied research, 1993-05, Vol.137 (1), p.K1-K3

1993

Volltextzugriff (PDF)

Effect of Statins on Platelet PAR-1 Thrombin Receptor in Patients With the Metabolic Syndrome (From the PAR-1 Inhibition by Statins [PARIS] Study)

The American journal of cardiology, 2006-05, Vol.97 (9), p.1332-1336

2006

Volltextzugriff (PDF)

Early Impact of Prescription Omega-3 Fatty Acids on Platelet Biomarkers in Patients with Coronary Artery Disease and Hypertriglyceridemia

Cardiology, 2011-01, Vol.118 (3), p.187-194

2011

Volltextzugriff (PDF)

Effect of aliskiren and valsartan combination versus aliskiren monotherapy on hemostatic biomarkers in hypertensive diabetics: Aliskiren and Valsartan Impact in Diabetics pilot trial

American journal of therapeutics, 2014-11, Vol.21 (6), p.482-490

2014

Volltextzugriff (PDF)

A Randomized Trial of Aspirin at Clinically Relevant Doses and Nitric Oxide Formation in Humans

Journal of cardiovascular pharmacology and therapeutics, 2010-12, Vol.15 (4), p.344-348

2010

Volltextzugriff (PDF)

Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting

Thrombosis and haemostasis, 2008-08, Vol.100 (2), p.314-318

2008

Volltextzugriff (PDF)

Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: The PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) Trial

The American heart journal, 2008, Vol.155 (1), p.93.e1-93.e7

2008

Volltextzugriff (PDF)

Spectrofluorimetric assessment of plasma dipyridamole stability: Sample storage for multicenter clinical trials?

Thrombosis research, 2008, Vol.123 (1), p.184-186

2008

Volltextzugriff (PDF)

Antiplatelet properties of escitalopram in patients with the metabolic syndrome : A dose-ranging in vitro study

Neuropsychopharmacology (New York, N.Y.), 2007-11, Vol.32 (11), p.2369-2374

2007

Volltextzugriff (PDF)

Effects of extended-release dipyridamole in vitro on thrombin indices measured by calibrated automated thrombography in poststroke survivors

American journal of therapeutics, 2012-11, Vol.19 (6), p.407-412

2012

Volltextzugriff (PDF)

Stability validation of paraformaldehyde-fixed samples for the assessment of the platelet PECAM-1, P-selectin, and PAR-1 thrombin receptor by flow cytometry

Journal of thrombosis and thrombolysis, 2010-07, Vol.30 (1), p.79-83

2010

Volltextzugriff (PDF)

Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: Hitting the TARGET in the TENACITY trial?

Thrombosis research, 2007-01, Vol.119 (2), p.175-181

2007

Volltextzugriff (PDF)

Monitoring platelet inhibition after clopidogrel with the Verify Now -P2Y12® rapid analyzer: The VERIfy Thrombosis risk ASsessment (VERITAS) study

Thrombosis research, 2007, Vol.119 (3), p.277-284

2007

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(27)

Sprache

Englisch
(26)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(21)
Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Female
(17)
Male
(17)
Middle Aged
(16)
Aged
(14)
Cardiovascular System & Cardiology
(13)
Biological And Medical Sciences
(12)
Medical Sciences
(12)
Ticlopidine - Analogs & Derivatives
(9)
Peripheral Vascular Disease
(8)
Pharmacology & Pharmacy
(8)
Platelets
(8)
Adult
(7)
Blood Platelets - Drug Effects
(7)
Flow Cytometry
(7)
Pharmacology. Drug Treatments
(7)
Platelet Aggregation - Drug Effects
(7)
Platelet Aggregation Inhibitors - Pharmacology
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel

Criticality of pH for accurate fluorometric measurements of dipyridamole levels in biological fluids

Escitalopram, but not its major metabolites, exhibits antiplatelet activity in humans

Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke : For the plavix use for treatment of stroke (PLUTO-stroke) trial

Dipyridamole Decreases Protease-Activated Receptor and Annexin-V Binding on Platelets of Poststroke Patients with Aspirin Nonresponsiveness

Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: A randomized, single-blind, 30-day trial

Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial

Criticaly of pH for accurate fluorometric measurements of dipyridamole levels in biological fluids

Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease

Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge

Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?

Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer : The VERify Thrombosis risk ASsessment (VERITAS) study

The Constant Magnetic Field Influence on Diffusion of63Ni in α-Fe

Effect of Statins on Platelet PAR-1 Thrombin Receptor in Patients With the Metabolic Syndrome (From the PAR-1 Inhibition by Statins [PARIS] Study)

Early Impact of Prescription Omega-3 Fatty Acids on Platelet Biomarkers in Patients with Coronary Artery Disease and Hypertriglyceridemia

Effect of aliskiren and valsartan combination versus aliskiren monotherapy on hemostatic biomarkers in hypertensive diabetics: Aliskiren and Valsartan Impact in Diabetics pilot trial

A Randomized Trial of Aspirin at Clinically Relevant Doses and Nitric Oxide Formation in Humans

Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting

Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: The PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) Trial

Spectrofluorimetric assessment of plasma dipyridamole stability: Sample storage for multicenter clinical trials?

Antiplatelet properties of escitalopram in patients with the metabolic syndrome : A dose-ranging in vitro study

Effects of extended-release dipyridamole in vitro on thrombin indices measured by calibrated automated thrombography in poststroke survivors

Stability validation of paraformaldehyde-fixed samples for the assessment of the platelet PECAM-1, P-selectin, and PAR-1 thrombin receptor by flow cytometry

Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: Hitting the TARGET in the TENACITY trial?

Monitoring platelet inhibition after clopidogrel with the Verify Now -P2Y12® rapid analyzer: The VERIfy Thrombosis risk ASsessment (VERITAS) study

Suchergebnisse filtern